C-met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 3, 2014, Pages 701-707

  Baschnagel, Andrew M ^a   Williams, Lindsay ^a   Hanna, Alaa ^a   Chen, Peter Y ^a   Krauss, Daniel J ^a   Pruetz, Barbara L ^a   Akervall, Jan ^a   Wilson, George D ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893845694     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.11.013     Document Type: Article

References (23)

1. J.P. Pignon, A. le Maitre, and E. Maillard et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients Radiother Oncol 92 2009 4 14
2. A.K. Chaturvedi, E.A. Engels, and R.M. Pfeiffer et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol 29 2011 4294 4301
3. K.K. Ang, J. Harris, and R. Wheeler et al. Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
4. K.K. Ang, B.A. Berkey, and X. Tu et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356 (Pubitemid 36025259)
5. S.M. Bentzen, B.M. Atasoy, and F.M. Daley et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial J Clin Oncol 23 2005 5560 5567
6. J.A. Bonner, P.M. Harari, and J. Giralt et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 2010 21 28
7. T.Y. Seiwert, R. Jagadeeswaran, and L. Faoro et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma Cancer Res 69 2009 3021 3031
8. B. Peruzzi, and D.P. Bottaro Targeting the c-Met signaling pathway in cancer Clin Cancer Res 12 2006 3657 3660 (Pubitemid 44000247)
9. G.R. Blumenschein Jr., G.B. Mills, and A.M. Gonzalez-Angulo Targeting the hepatocyte growth factor-cMET axis in cancer therapy J Clin Oncol 30 2012 3287 3296
10. D.M. Aebersold, A. Kollar, and K.T. Beer et al. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation Int J Cancer 96 2001 41 54 (Pubitemid 32147684)
11. C.H. Kim, Y.W. Koh, and J.H. Han et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma Head Neck 32 2010 1655 1664
12. Y.C. Lim, J.H. Han, and H.J. Kang et al. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma Oral Oncol 48 2012 1114 1119
13. L. Lo Muzio, A. Farina, and C. Rubini et al. Effect of c-Met expression on survival in head and neck squamous cell carcinoma Tumour Biol 27 2006 115 121
14. D.D. Marshall, and L.J. Kornberg Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma Laryngoscope 108 1998 1413 1417 (Pubitemid 28411378)
15. Y.J. Kim, H. Go, and H.G. Wu et al. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy Head Neck 33 2010 1458 1466
16. A. Argiris, M. Ghebremichael, and J. Gilbert et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An Eastern Cooperative Oncology Group trial J Clin Oncol 31 2013 1405 1414
17. H. Xu, L.P. Stabile, and C.T. Gubish et al. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells Clin Cancer Res 17 2011 4425 4438
18. J. Akervall, X. Guo, and C.N. Qian et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients Clin Cancer Res 10 2004 8204 8213 (Pubitemid 40053379)
19. L.P. Stabile, G. He, and V.W. Lui et al. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met Clin Cancer Res 19 2013 380 392
20. S. Peters, and A.A. Adjei MET: A promising anticancer therapeutic target Nat Rev Clin Oncol 9 2012 314 326
21. L.M. Knowles, L.P. Stabile, and A.M. Egloff et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer Clin Cancer Res 15 2009 3740 3750
22. D.N. Hayes, J. Grandis, and A.K. El-Naggar Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas April 2013 In American Association for Cancer Research Annual Meeting Washington, DC
23. D.L. Wheeler, S. Huang, and T.J. Kruser et al. Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members Oncogene 27 2008 3944 3956 (Pubitemid 351913636)